8th TBPK – Presentations

Clofazimine: current status and future prospects
Dr. E. Nuermberger
Penetration of rifampin and rifapentine into diseased lung in the rabbit cavity pulmonary disease model of TB
Dr. D. Rifat
Population pharmacokinetics and penetration of first and second line anti-TB drugs in pulmonary lesions from adults with active tuberculosis
Dr. S. Gupta
Model based evaluation of higher doses of rifampicin using a semi-mechanistic model incorporating auto-induction and saturation of hepatic extraction
Dr. P. Denti
The Pharmacokinetics/Pharmacodynamics of Delamanid
Dr. S. Mallikaarjun
Pharmacokinetics and pharmacodynamics of pyrazinoic acid in murine models of tuberculosis
Dr. J. Lanoix
Pharmacodynamics of sulfamethoxazole in in vitro and in vivo models of tuberculosis
Dr. E. Nuermberger
Pharmacokinetics of rifampicin and moxifloxacin in the PanACEA-MAMS-TB-01 trial
Dr. R. Aarnoutse
Contribution of different oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in murine models of tuberculosis
Dr. E. Nuermberger
The Systems Pharmacology approach to improve TB treatment
Dr. R. Savic
Concentration-response effects of combination therapy in a murine model of tuberculosis: optimizing the dosing regimen for short-course therapy
Dr. N. Zhang
Association of anti-tuberculosis drug concentrations with drug-related adverse events in TB/HIV co-infected patients in Uganda
Dr. C. S Wiltshire
Dose optimization for combinations of three or more drugs: an application to dose selection in regimen-based tuberculosis drug development
Dr. M. Lyons
Mathematical model of drug-target binding predicts optimal antibiotic treatment
Dr. P. Abel zur Wiesch
TB and diabetes mellitus: pharmacological aspects of the convergence of two epidemics
Dr. R. Ruslami
Digitizing MTB Medicines: Using compounding methods to enable mobile capture of MTB medication adherence
Dr. S. Browne
Prediction of drug partitioning into tubercular pulmonary lesions
Dr. C. Chen
Drug Partitioning and Local Microenvironmental Conditions affect Bedaquiline, Clofazimine and Pyrazinamide Treatment Responses in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice
Dr. S. Irwin
Quantitative modeling of time to positivity following dosing of bedaquiline and rifafour in patients with pulmonary tuberculosis infection
Dr. J.F. Marier